Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $22.06
  • 50 Day Moving Average: $25.56
  • 200 Day Moving Average: $26.65
  • 52-Week Range: $347,535,000.00 - $18.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 2.83
  • P/E Growth: 0.33
  • Market Cap: $7.63B
  • Outstanding Shares: 347,535,000
  • Beta: -0.14
  • Net Margins: -9.29%
  • Return on Equity: 46.59%
  • Return on Assets: 5.68%
  • Debt-to-Equity Ratio: 5.70%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.06%
Additional Links:
Companies Related to Valeant Pharmaceuticals International:

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (?)
Ratings Breakdown: 4 Sell Ratings, 14 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: $52.08 (137.17% upside)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateFirmActionRatingPrice TargetDetails
10/18/2016Wells Fargo & Co.Reiterated RatingUnderperform$19.50View Rating Details
10/14/2016Deutsche Bank AGLower Price TargetHold$30.00 -> $29.00View Rating Details
10/12/2016RBC Capital MarketsReiterated RatingSector Perform$36.00 -> $47.50View Rating Details
10/12/2016Royal Bank Of CanadaLower Price TargetSector Perform$36.00 -> $35.00View Rating Details
9/7/2016Morgan StanleyReiterated RatingOverweight$42.00View Rating Details
8/19/2016Piper Jaffray Cos.Set Price TargetSell$22.00View Rating Details
8/19/2016Canaccord GenuityReiterated RatingHold$31.00 -> $33.00View Rating Details
8/18/2016MizuhoReiterated RatingUnderperform$11.00View Rating Details
8/13/2016TD SecuritiesReiterated RatingBuy$38.00View Rating Details
8/11/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
8/10/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuy$40.00View Rating Details
8/9/2016Rodman & RenshawLower Price TargetBuy$90.00 -> $81.00View Rating Details
7/26/2016ScotiabankReiterated RatingSector Perform$35.00 -> $32.00View Rating Details
7/25/2016JPMorgan Chase & Co.Set Price TargetHold$35.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00View Rating Details
7/6/2016Stifel NicolausReiterated RatingBuy$55.00View Rating Details
6/7/2016Barclays PLCReiterated RatingHold$34.00View Rating Details
5/29/2016SusquehannaReiterated RatingHold$105.00View Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00View Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00View Rating Details
12/21/2015Bank of America Corp.Reiterated RatingBuyView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldView Rating Details
11/2/2015Goldman Sachs Group Inc.DowngradeBuy -> Neutral$180.00 -> $122.00View Rating Details
10/23/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyView Rating Details
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00View Rating Details
7/10/2015Howard WeilInitiated CoverageOutperform$290.00View Rating Details
4/30/2015Cantor FitzgeraldBoost Price TargetBuy$222.00 -> $271.00View Rating Details
2/25/2015CRT CapitalBoost Price TargetBuy$180.00 -> $220.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
Current Year EPS Consensus Estimate: $6.53 EPS
Next Year EPS Consensus Estimate: $7.75 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$1.60$1.60$1.60
Q3 20161$1.83$1.83$1.83
Q4 20161$2.10$2.10$2.10
(Data provided by Zacks Investment Research)


Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Ownership Percentage: 16.37%
Institutional Ownership Percentage: 63.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
DateHeadline logoJim Chanos uses this 7-point checklist for companies he's going to short (NYSE:VRX) - October 19 at 7:39 PM
News IconQuarterly Financial Watch for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - The Newburgh Press (NYSE:VRX) - October 18 at 7:50 PM
News IconStock Roundup - Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Hot Stocks Point (NYSE:VRX) - October 18 at 7:50 PM
News IconHottest Canadian ADRs Now: Kinross Gold Corporation (KGC ... - The Independent Republic (NYSE:VRX) - October 18 at 7:50 PM logoValeant: Another Philidor? - Valeant Pharmaceuticals International ... - Seeking Alpha (NYSE:VRX) - October 18 at 7:50 PM logoDeferred Tax Assets Of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) At $193.3 - (NYSE:VRX) - October 17 at 7:53 PM logoPharma Stocks Prone to Decline From Democratic Win (MYL, ARIA) (NYSE:VRX) - October 17 at 7:53 PM logo5 Things You Must Know Before the Market Opens Monday (NYSE:VRX) - October 17 at 6:58 AM
News IconShare Value Diminishing Over Past Month: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - CSZ News (NYSE:VRX) - October 16 at 7:03 AM
News IconTaking Aim at Future Earnings Predictions for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - CSZ News (NYSE:VRX) - October 15 at 6:57 AM logoValeant announces price increases of 2% to 9% for neurology, gastrointestinal disorders and urology portfolios (NYSE:VRX) - October 14 at 7:51 PM logoValeant Raises Prices On Certain Products (NYSE:VRX) - October 14 at 7:51 PM logoCompany Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc’s Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions (NYSE:VRX) - October 14 at 7:51 PM logoValeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions (NYSE:VRX) - October 14 at 7:51 PM logoRuane Cunniff Makes One Significant Buy (NYSE:VRX) - October 13 at 8:15 PM
News IconStocks Luring Investors Focus: Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Tokai Pharmaceuticals, Inc ... - Street Wise Report (press release) (blog) (NYSE:VRX) - October 13 at 12:03 PM logoValeant: Profits Vs. Childrens' Health - Seeking Alpha (NYSE:VRX) - October 13 at 12:03 PM
News IconAnalyst's Review on:Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (NYSE:VRX) - October 12 at 8:02 PM logoThe Pharmaceutical Sector Looks Attractive (NYSE:VRX) - October 12 at 8:02 PM logoWhy Should You Avoid Valeant For Now - Seeking Alpha (NYSE:VRX) - October 12 at 12:58 PM logoWhy Should You Avoid Valeant For Now (NYSE:VRX) - October 11 at 7:47 PM logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) Deferred Tax Assets At $193.3 - (NYSE:VRX) - October 11 at 6:49 AM
News IconAnalyst Review: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - NewsDen (NYSE:VRX) - October 11 at 6:49 AM
News IconActive Frontline Stocks in Broker Choice: Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Medtronic plc ... - Street Wise Report (press release) (blog) (NYSE:VRX) - October 11 at 6:49 AM logoAvoid Valeant Amid Philidor Debacle (NYSE:VRX) - October 10 at 7:29 PM
News Icon5 Year Capital Spending Growth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is reported at 78.32 - Newburgh Press (NYSE:VRX) - October 8 at 7:04 AM logoValeant Or Deutsche Bank? - Valeant Pharmaceuticals International ... - Seeking Alpha (NYSE:VRX) - October 8 at 7:04 AM logoValeant Pharma (VRX) Names New Chief Quality Officer - (NYSE:VRX) - October 7 at 7:10 AM logoValeant Pharmaceuticals International Becomes Oversold (VRX) - Forbes (NYSE:VRX) - October 7 at 7:10 AM logo4:21 pm Valeant Pharma appoints Louis W. Yu, Ph.D. to the newly created position of Chief Quality Officer, Global Quality (NYSE:VRX) - October 6 at 7:46 PM
News IconPharming Reports on Extraordinary General Meeting of Shareholders (NYSE:VRX) - October 5 at 7:49 PM
News IconValeant Pharmaceuticals International (VRX) Shares are Down -11.44% (NYSE:VRX) - October 5 at 7:49 PM
News IconSell-side Target Update on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - CSZ News (NYSE:VRX) - October 5 at 7:13 AM logoValeant: $37 Per Share Target - Seeking Alpha (NYSE:VRX) - October 4 at 7:28 PM
News IconLegal Worries Continue To Weigh On Valeant Pharmaceuticals Intl Inc (VRX) Stock (NYSE:VRX) - October 3 at 7:25 PM
News IconConsensus Weighing in on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Recall News (NYSE:VRX) - October 3 at 7:43 AM logoAP Top Extended Financial Headlines at 7:37 a.m. EDT (NYSE:VRX) - October 3 at 7:43 AM logoValeant's Regulatory Nightmare - Seeking Alpha (NYSE:VRX) - October 2 at 6:58 AM logoBetter Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc - Motley Fool (NYSE:VRX) - October 1 at 8:26 AM logoValeant Can Go Bankrupt (NYSE:VRX) - September 30 at 7:14 PM logoHow Valeant’s Scandal Has Impacted Its Stock Price (VRX) (NYSE:VRX) - September 30 at 7:14 PM
News IconValeant Pharmaceuticals International, Inc. (NYSE:VRX) could surge as high as $175 - Newburgh Press (NYSE:VRX) - September 30 at 7:16 AM logoValeant: Is Bankruptcy Possible? - Seeking Alpha (NYSE:VRX) - September 29 at 7:01 AM logoValeant Pharmaceuticals International, Inc. – Value Analysis (NYSE:VRX) : September 28, 2016 (NYSE:VRX) - September 28 at 7:47 PM logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) : Quarterly EPS At $2.01 - Investor Newswire (NYSE:VRX) - September 27 at 9:44 AM logoValeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bearish Manner : VRX-US : September 27, 2016 (NYSE:VRX) - September 27 at 9:44 AM logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) Accounts Payable At $425.9 - (NYSE:VRX) - September 26 at 8:00 PM
News IconFinancial Watchlist of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Newburgh Press (NYSE:VRX) - September 26 at 8:00 PM
News IconStock under Consideration- Valeant Pharmaceuticals International, Inc.'s (VRX) - Hot Stocks Point (NYSE:VRX) - September 25 at 6:49 AM logoValeant Pharmaceuticals: How Much Downside? - Seeking Alpha (NYSE:VRX) - September 25 at 6:49 AM


Valeant Pharmaceuticals International (NYSE:VRX) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff